Richard J Honeywell

List of Publications by Year
in descending order

37 papers	774 citations	567281 15 h-index	526287 27 g-index
37 all docs	37 docs citations	37 times ranked	1451 citing authors

#	Article	IF	Citations
1	Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance. Clinical Cancer Research, 2011, 17, 7337-7346.	7.0	275
2	Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib. Cellular Oncology (Dordrecht), 2015, 38, 119-129.	4.4	46
3	Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance. Cancers, 2018, 10, 503.	3.7	44
4	Inhibition of thymidylate synthase by 2â€²,2â€²-difluoro-2â€²-deoxycytidine (Gemcitabine) and its metabolite 2â€²,2â€²-difluoro-2â€²-deoxyuridine. International Journal of Biochemistry and Cell Biology, 2015, 60, 73-81.	2.8	41
5	Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib. Expert Review of Anticancer Therapy, 2016, 16, 147-157.	2.4	33
6	Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction. Cancer Medicine, 2015, 4, 1003-1015.	2.8	29
7	Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature. Oncoscience, 2014, 1, 844-853.	2.2	26
8	Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine. SpringerPlus, 2014, 3, 732.	1.2	23
9	Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR. Oncotarget, 2016, 7, 5240-5257.	1.8	23
10	Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab. Angiogenesis, 2018, 21, 325-334.	7.2	20
11	DNA methyltransferases expression in normal tissues and various human cancer cell lines, xenografts and tumors.. Nucleosides, Nucleotides and Nucleic Acids, 2018, 37, 696-708.	1.1	19
12	Coexisting Molecular Determinants of Acquired Oxaliplatin Resistance in Human Colorectal and Ovarian Cancer Cell Lines. International Journal of Molecular Sciences, 2019, 20, 3619.	4.1	19
13	Physicochemical properties of novel protein kinase inhibitors in relation to their substrate specificity for drug transporters. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 703-717.	3.3	18
14	Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth. Journal of Experimental and Clinical Cancer Research, 2016, 35, 138.	8.6	17
15	RX-3117 (fluorocyclopentenyl cytosine): a novel specific antimetabolite for selective cancer treatment. Expert Opinion on Investigational Drugs, 2019, 28, 311-322.	4.1	17
16	Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors. Journal of Clinical Oncology, 2019, 37, 411-418.	1.6	16
17	Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study. British Journal of Cancer, 2018, 119, 1326-1331.	6.4	15
18	Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma. Clinical Cancer Research, 2022, 28, 1595-1602.	7.0	12

#	Article	IF	Citations
19	Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome. Cancers, 2020, 12, 330.	3.7	11
20	Breastfeeding during R-CHOP chemotherapy: please abstain!. European Journal of Cancer, 2019, 119, 107-111.	2.8	10
21	Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance. Cancers, 2020, 12, 3322.	3.7	10
22	Determination of the Phosphorylated Metabolites of Gemcitabine and of Difluorodeoxyuridine by LCMSMS. Nucleosides, Nucleotides and Nucleic Acids, 2011, 30, 1203-1213.	1.1	9
23	Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?. British Journal of Clinical Pharmacology, 2019, 85, 1213-1214.	2.4	7
24	Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function. Journal of Cellular Physiology, 2020, 235, 8085-8097.	4.1	7
25	Transport of six tyrosine kinase inhibitors: active or passive?. ADMET and DMPK, 2016, 4, 23.	2.1	7
26	Sensitive liquid chromatography mass spectrometry (LC-MS) assay reveals novel insights on DNA methylation and incorporation of gemcitabine, its metabolite difluorodeoxyuridine, deoxyuridine, and RX-3117 into DNA. Nucleosides, Nucleotides and Nucleic Acids, 2016, 35, 652-662.	1.1	4
27	The prognostic impact of circulating miRNAs in patients with advanced esophagogastric cancer during palliative chemotherapy. Cancer Treatment and Research Communications, 2021, 27, 100371.	1.7	4
28	Adaptation of a human gut epithelial model in relation to the assessment of clinical pharmacokinetic parameters for selected tyrosine kinase inhibitors. ADMET and DMPK, 2015, 3, .	2.1	3
29	Subcellular localization of several structurally different tyrosine kinase inhibitors. ADMET and DMPK, 2018, 6, 258-266.	2.1	3
30	Carboplatin Dosing in Children Using Estimated Glomerular Filtration Rate: Equation Matters. Cancers, 2021, 13, 5963.	3.7	3
31	Tumor, skin, and plasma concentrations of protein kinase inhibitors (PKIs) in patients with advanced cancer.. Journal of Clinical Oncology, 2013, 31, 11087-11087.	1.6	2
32	A phase 1/2 study of intermittent, high dose sunitinib in patients with advanced solid tumors.. Journal of Clinical Oncology, 2017, 35, 2591-2591.	1.6	1
33	11C-sorafenib and 15O-H2O PET for early evaluation of sorafenib therapy. Journal of Nuclear Medicine, 2020, 62, jnumed.120.251611.	5.0	0
34	A phase 1 study of weekly high dose sunitinib in patients with advanced solid tumors: Early signs of activity in non-RCC tumor types.. Journal of Clinical Oncology, 2015, 33, e13550-e13550.	1.6	0
35	Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer (AEGC).. Journal of Clinical Oncology, 2016, 34, e15555-e15555.	1.6	0
36	Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: A phase I exposure escalation study.. Journal of Clinical Oncology, 2017, 35, TPS2620-TPS2620.	1.6	0

#	Article	IF	Citations
37	Prospective study on the role of cytidine deaminase activity in lung cancer patients treated with gemcitabine-platinum-based chemotherapy.. Journal of Clinical Oncology, 2018, 36, e24078-e24078.	1.6	0